(MedPage Today)-Chemotherapy improved in the first line (Tagrisso) in addition to a largely chemotherapy versus unilateral Osimerinib in patients with NSCLC. Of a total of 557 patients, and …
Winning in general to survive for Osimrtinib-Chemoth therapy